论文部分内容阅读
[目的]评价长春瑞滨(NVB)联合顺铂(DDP)的NP方案治疗蒽环类耐药晚期乳腺癌患者的疗效和不良反应。[方法]2007年10月至2011年10月采用NP方案治疗蒽环类耐药的晚期乳腺癌42例。长春瑞滨25mg/m2加入生理盐水20ml,静脉推注,d1,5,顺铂25mg/m2静脉滴注,d1～3,21d为1个周期。[结果]42例乳腺癌共完成171个化疗周期。完全缓解(CR)2例(4.8%),部分缓解(PR)19例(45.2%),稳定(SD)14例(33.3%),进展(PD)7例(16.7%)。有效率(CR+PR)为50.0%,肿瘤控制率(CR+PR+SD)为83.3%。有内脏转移患者的疗效低于无内脏转移者(39.3%vs71.4%,P=0.05)。主要不良反应为骨髓抑制及胃肠道反应。[结论]长春瑞滨联合顺铂治疗蒽环类耐药性晚期乳腺癌疗效较好,毒副反应可以耐受。
[Objective] To evaluate the efficacy and adverse reactions of NP regimen of vinblastine (NVB) combined with cisplatin (DDP) in patients with advanced anthracycline-resistant breast cancer. [Method] From October 2007 to October 2011, 42 cases of advanced anthracycline-resistant breast cancer were treated with NP regimen. Vinorelbine 25mg / m2 added saline 20ml, intravenous bolus, d1,5, cisplatin 25mg / m2 intravenous infusion, d1 ~ 3,21 d for a cycle. [Results] A total of 171 cycles of chemotherapy were completed in 42 cases of breast cancer. There were 2 cases (4.8%) of complete remission (CR), 19 cases (45.2%) of partial remission (PR), 14 cases (33.3%) of stable (SD) and 7 cases (16.7%) of progress (PD). The effective rate (CR + PR) was 50.0%, and the tumor control rate (CR + PR + SD) was 83.3%. Patients with visceral metastases were less effective than those without visceral metastases (39.3% vs 71.4%, P = 0.05). The main adverse reactions were myelosuppression and gastrointestinal reactions. [Conclusion] vinorelbine combined with cisplatin is effective in treating anthracycline-resistant advanced breast cancer and its toxicity can be tolerated.